Shares in Celcuity climbed by 233.76% at market open on 28 July after it reported the Phase III breast cancer data.

A research project led by the Ineos Oxford Institute for antimicrobial research (IOI) to study the cause and impact of ...

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

SUZHOU, China, July 29, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation ...

A team of Toronto researchers has received Health Canada approval to conduct clinical trials for a novel class of ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...

Answer ALS, a large-scale research initiative headquartered in New Orleans and Washington, D.C., has announced the launch of ...

The ongoing Phase I/IIa study (NCT04725331) is a multicenter, open label, dose-escalation study evaluating BT-001 as a single agent and in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) ...

Study highlights novel epigenomic modulation in the central nervous system as a key mechanism for SRP-001's analgesic effects ...

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal ...